Viking Therapeutics (VKTX) is generating significant buzz among analysts, with a consensus one-year price target set at $93.59—over 170% higher than its current price. This optimism stems from Viking’s weight-loss drug VK2735, which is currently in phase 3 trials and has shown promising results, achieving an average weight loss of 14.7% in just 13 weeks. This positions Viking as a potential competitor to established players like Novo Nordisk and Eli Lilly, despite the challenges it faced with its oral formulation.
The weight-loss drug market is poised for explosive growth, projected to expand from $26 billion last year to over $130 billion by 2031. Analysts believe that VK2735’s unique dual agonist approach, which combines GLP-1 and GIP therapies, offers a competitive edge in terms of tolerability and efficacy compared to existing options. The overall sentiment remains bullish, with many analysts considering VKTX a strong buy as they anticipate positive Phase 3 trial results.
For market professionals, the key takeaway is that Viking Therapeutics represents a high-risk, high-reward opportunity in the biopharma sector. With a strong analyst backing and a potentially transformative drug in the pipeline, VKTX could be a compelling addition for those looking to capitalize on the burgeoning anti-obesity market.
Source: fool.com